Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Jimenez Jose L.; Tighiouart Mourad; Gasparini Mauro

首页> 外文期刊>Biometrical Journal >Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

【24h】

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

机译：癌症期I试验设计使用药物组合当一小部分含有限制毒性归因于一个或多个药剂时

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Biometrical Journal》 |2019年第2期|共14页
作者
Jimenez Jose L.; Tighiouart Mourad; Gasparini Mauro;
展开▼
作者单位

Politecnico di TorinoDipartimento di Scienze MatematicheCorso Duca degli Abruzzi 24 10129 Turin Italy;

Samuel Oschin Comprehensive Cancer InstituteLos Angeles CA 90048 USA;

Politecnico di TorinoDipartimento di Scienze MatematicheCorso Duca degli Abruzzi 24 10129 Turin Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类生物学实验与观测;
关键词
attributable toxicity; cancer phase I trials; continual reassessment method; copula type models; drug combination;

机译：归因于毒性;癌症期我试验;连续重新评估方法;Copula型模型;药物组合;

相似文献

外文文献
中文文献
专利

1. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents [J] . Jimenez Jose L., Tighiouart Mourad, Gasparini Mauro Biometrical Journal . 2019,第2期

机译：癌症期I试验设计使用药物组合当一小部分含有限制毒性归因于一个或多个药剂时
2. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. [J] . Le Tourneau C, Razak AR, Gan HK, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第10期

机译：分子靶向药物在I期癌症临床试验的剂量限制性毒性定义中的异质性：文献综述。
3. Two-stage design for phase Ⅰ-Ⅱ cancer clinical trials using continuous dose combinations of cytotoxic agents [J] . Tighiouart Mourad Journal of the royal statistical society . 2019,第PTa1期

机译：连续剂量组合的细胞毒剂用于Ⅰ-Ⅱ期癌症临床试验的两阶段设计
4. The Combination of Clinical, Dose-Related and Imaging Features Helps Predict Radiation-Induced Normal-Tissue Toxicity in Lung-cancer Patients -- An in-silico Trial Using Machine Learning Techniques [C] . Nalbantov G., Dekker A., De Ruysscher D., Machine Learning and Applications and Workshops (ICMLA), 2011 10th International Conference on . 2011

机译：临床，剂量相关和影像学特征的结合可帮助预测肺癌患者放射诱发的正常组织毒性-使用机器学习技术的计算机模拟试验
5. Enhancing the Therapeutic Effects of Low Doses of Ionizing Radiation in Non-Small Cell Lung Cancers Using a Combination of PARP Inhibitors and DNA Demethylating Agents. [D] . Biondi, Christopher Anthony. 2016

机译：使用PARP抑制剂和DNA去甲基化剂的组合增强非小细胞肺癌低剂量电离辐射的治疗效果。
6. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents [O] . Jose L. Jimenez, Mourad Tighiouart, Mauro Gasparini -1

机译：当部分剂量限制性毒性可归因于一种或多种药物时使用药物组合的癌症I期试验设计
7. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents [O] . Jimenez, Jose L., Tighiouart, Mourad, Gasparini, Mauro 2017

机译：癌症I期试验设计使用药物组合时的一小部分剂量限制毒性可归因于一种或多种药剂

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

著录项

引文网络

相似文献

相关主题

期刊订阅